230 related articles for article (PubMed ID: 18769124)
1. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.
Raja SM; Clubb RJ; Bhattacharyya M; Dimri M; Cheng H; Pan W; Ortega-Cava C; Lakku-Reddi A; Naramura M; Band V; Band H
Cancer Biol Ther; 2008 Oct; 7(10):1630-40. PubMed ID: 18769124
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
3. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
[TBL] [Abstract][Full Text] [Related]
4. ErbB2 degradation mediated by the co-chaperone protein CHIP.
Zhou P; Fernandes N; Dodge IL; Reddi AL; Rao N; Safran H; DiPetrillo TA; Wazer DE; Band V; Band H
J Biol Chem; 2003 Apr; 278(16):13829-37. PubMed ID: 12574167
[TBL] [Abstract][Full Text] [Related]
5. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
[TBL] [Abstract][Full Text] [Related]
6. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
[TBL] [Abstract][Full Text] [Related]
7. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?
Arteaga CL
Clin Cancer Res; 2011 Aug; 17(15):4919-21. PubMed ID: 21670086
[TBL] [Abstract][Full Text] [Related]
8. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
[TBL] [Abstract][Full Text] [Related]
9. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
[TBL] [Abstract][Full Text] [Related]
10. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
[TBL] [Abstract][Full Text] [Related]
11. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.
Austin CD; De Mazière AM; Pisacane PI; van Dijk SM; Eigenbrot C; Sliwkowski MX; Klumperman J; Scheller RH
Mol Biol Cell; 2004 Dec; 15(12):5268-82. PubMed ID: 15385631
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
[TBL] [Abstract][Full Text] [Related]
13. c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway.
Oshikawa G; Nagao T; Wu N; Kurosu T; Miura O
J Biol Chem; 2011 Sep; 286(35):30263-30273. PubMed ID: 21768087
[TBL] [Abstract][Full Text] [Related]
14. ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.
Marx C; Held JM; Gibson BW; Benz CC
Cancer Res; 2010 May; 70(9):3709-17. PubMed ID: 20406983
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
16. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Huang X; Wang S; Lee CK; Yang X; Liu B
Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
[TBL] [Abstract][Full Text] [Related]
18. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
[TBL] [Abstract][Full Text] [Related]
19. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase C mediated internalization of ErbB2 is independent of clathrin, ubiquitination and Hsp90 dissociation.
Dietrich M; Malik MS; Nikolaysen F; Skeie M; Stang E
Exp Cell Res; 2018 Oct; 371(1):139-150. PubMed ID: 30098331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
